KOTAI Biotechnology, Inc. and 3H Holdings Inc. utilize “Rare Disease Research and Development Program based on patient-centered principle” and call for patient participation in “Study of Specific Immune Conditions of Autoimmune Diseases”.
KOTAI Biotechnology, Inc. (Kazuo Yamashita, CEO, hereinafter referred to as “KOTAI”) and 3H Holdings Inc. (Sho Ando, CEO, formerly CROee, hereinafter referred to as “3H”) has released the information on “Study of Specific Immune Conditions of Autoimmune Diseases” conducted by KOTAI at the intractable disease and rare disease information site, “RareS.”, (https://raresnet.com/special/pcrd2-pro01/), in order to utilize “Patient Centricity in Rare Disease R&D Program, hereinafter referred to as “PCRD²” and call for of research cooperation among autoimmune disease patients. This is the first study of PCRD² jointly conducted by the University of Tokyo and 3H Holdings Inc.